Kidney cancer is one of the most common cancers of the urinary system, with clear cell renal cell carcinoma (ccRCC) being the most frequent pathological type. However, adjuvant therapy after surgery for localized ccRCC has historically been a challenging area of research, with limited success documented. In 2021, pembrolizumab, PD-1 antibody, was approved as an adjuvant treatment for renal cell carcinoma (RCC) patients based on significant improvements in disease-free survival (DFS) observed in the phase 3 KEYNOTE-564 trial. The recent publication of the third prespecified interim analysis of the trial has demonstrated that adjuvant pembrolizumab was also associated with a significant and clinically meaningful improvement in OS among ccRCC patients at increased risk for recurrence after surgery.

Osimertinib is a third-generation, orally administered epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) previously approved for the first-line treatment of EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).1,2 Results from the phase 3 FLAURA trial showed that os

Enzalutamide, a novel hormonal therapy (NHT), in combination with androgen deprivation therapy (ADT), has emerged as one of the novel treatment options for metastatic hormone-sensitive prostate cancer (mHSPC).1 The latest guidelines from the American Society of Clinical Oncology (ASCO) recommend the